anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
To accomplish this aim the investigators propose to complete one main experiment. The investigators will use iTMS and/or an acoustic startle stimuli to test the hypothesis that induced-plasticity protocols (iTMS and startle stimuli) will enhance EMG and force output in hand muscles during grasping. In a randomized sham crossover design, SCI and controls will be assigned to two groups: (1) iTMS applied during precision and power grip (two randomized sessions), and (2) startle applied during precision and power grip (two randomized sessions).
When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner pause the advancement for 10 sec. Next, the practitioner re-advance it to the pulmonary artery.
<P>PROBLEM TO BE SOLVED: To provide a blood purifying body capable of purifying blood by contact with the skin of the human body.  <P>SOLUTION: The blood purifying body is composed of: the first material selected from a group consisting of a copper material, a platinum material and molybdenum material; the second material selected from a group consisting of a black silica material, a radon material, a germanium material, an Nd material and a silica material; and a titanium oxide material. At least the titanium oxide material is disposed in the contact part in contact with the skin of the user. The contact part is composed of a blended coating layer 12 containing the second material and the titanium oxide material, or composed of a surface coating layer 23 including the titanium oxide material. An intermediate coating layer 22 including the second material and a cover base 21 are disposed in this order under the surface coating layer 23.  <P>COPYRIGHT: (C)2007,JPO&INPIT
PURPOSE:To obtain a composition for the oral cavity, containing aluminum hydroxide having specific properties as a polishing agent, having moderate polishing power and excellent in feeling of use with hardly any damage to teeth. CONSTITUTION:The objective substance, obtained by containing aluminum hydroxide having 5-14mum average particle diameter substantially without containing particles having >=44mum particle diameter and further >=20mum.m<2>/g, preferably 12-19mum.m<2>/g product of the average particle diameter and specific surface area as a polishing agent, then suitably blending an ester-based perfume, fluorine compound, surfactant, sweetening agent, etc., therewith and preparing a composition. The above-mentioned aluminum hydroxide is contained in an amount of normally 5-80% and 20-60% in the case of toothpaste. The composi tion can be prepared in the form of the toothpaste, wet dentifrice, prophylactic paste, etc. The composition is capable of preventing the perfume from deteriorat ing and perfuming is kept for a long period. The fluorine compound, if blended therein, is hardly deactivated and the residual amount of available fluorine is high even after preservation for a long period.
Pharmacokinetic differences between children and adults have resulted in recommended doses of abacavir based on weight that are higher for children than for adults. There are insufficient data to determine whether the pediatric or adult dose is more appropriate for HIV-infected adolescent patients. This study measures pharmacokinetic data for abacavir in the adolescent population so that an appropriate dosage can be determined.

Patients are evenly enrolled into 2 groups based on Tanner Stage. Group I patients are Tanner Stage 1 or 2 (pre-pubertal). Group II patients are Tanner Stage 3, 4, or 5 (pubertal). Each patient receives a single oral dose of abacavir given as the commercially available oral solution. Pharmacokinetic blood samples are collected before dosing and at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4, 6, and 8 hours post dose for abacavir concentrations.
Obstructive sleep apnea-hypopnea syndrome is the most common form of SRBDs. Recurrent hypoxia, that accompanies OSAHS increases the degradation of ATP, which in turn increase uric acid concentration that can be used as a biomarker of tissue hypoxia in OSAHS. There is still debate about whether OSAHS is an independent contributor to pulmonary arterial hypertension.

AIM OF THE WORK This study aimed to correlate serum uric acid levels and PAH in OSAHS patients. Methods We enrolled 100 patients diagnosed with OSAHS using polysomnography. Patients were divided into three severity groups: mild OSA (5 ≤ AHI \< 15), moderate OSA (15 ≤ AHI \< 30), and severe (30 ≤ AHI \< 60). Serum uric acid was measured the morning after polysomnography. All patients underwent standard echocardiograms, and Pulmonary artery systolic pressure calculation was done.
The invention belongs to the technical field of traditional Chinese medicine and relates to a traditional Chinese medicine composition with a gastric mucosa protecting function. The traditional Chinese medicine composition is prepared from 1000-2500 parts of hericium erinaceus, 150-500 parts of radix codonopsis, 100-400 parts of atractylodes macrocephala koidz, 100-400 parts of common bletilla pseudobulb and 50-300 parts of fructus amomi. The traditional Chinese medicine composition is prepared through a method including the steps that hericium erinaceus, common bletilla pseudobulb, fructus amomi, atractylodes macrocephala koidz and radix codonopsis are weighed and decocted for 2-3 times with water, 8-12 folds of water is added each time, the materials are soaked for 1-2 h before each time of decoction, decoction lasts for 1-2 h, and the decoction solutions obtained each time are filtered, combined, concentrated and dried. The five traditional Chinese medicines are combined for use and used for assisting in the gastric mucosa protecting function. A good effect can be achieved. Cinnamon is added on the basis of the formula, can assist in the middle warmer warning function of fructus amomi, can guide fire to the origin, promotes improvement of viscera functions and can enhance the function of assisting in gastric mucosa protection. The composition has no dependency if taken for a long time, body accumulation does not exist, drug resistance does not exist, the composition is safe, free of toxic and side effects and accurate in gastric mucosa protecting function assistance.
The invention relates to attapulgite mouth paste and paster. A main material and auxiliary materials are comprised. The main material is attapulgite. The paste or paster prepared by the invention can be placed at the focus to absorb pathogenic bacteria for a long time. The paste or paster cannot be dispersed by mouth secretion, so that the curative effect is improved. The paste or paster is convenient and practical and suitable for popularization and use in batches.
Invasive cribriform carcinoma (ICC) is a type of malignant tumor with slow growth and good prognosis. The study was a single center retrospective study. The percentage of ICC among patients diagnosed with breast cancer was 0.3% (8/2454 patients). All patients tested positive for estrogen or progesterone receptors and 12.5% (1/8) patients tested positive for human epidermal growth factor receptor type2 (HER2). The present study suggests that the clinicopathological features of ICC are low-grade hormone receptor-positive luminal type with a good prognosis. However, some patients were HER2-positive and require careful follow-up.
Purpose: To investigate clinical outcomes of transcrestal maxillary sinus floor elevation performed with an injectable xenograft in gel form, analyzing variables possibly influencing the results. Methods: Patients needing unilateral sinus floor elevation (residual crestal height \<5 mm) for the placement of a single implant were enrolled. Xenograft in gel form was injected through a crestal antrostomy in order to elevate sinus membrane and fill the sub-antral space. Simultaneous implant placement was performed when adequate primary stability was achievable. Graft height was measured immediately after surgery (T0) and after six months of healing (T1). Univariate and multivariate regression models were built to assess associations between clinical variables with implant survival and graft height at T1.
Many studies have shown a strong correlation between Hindgut Acidosis (HGA) and the occurrence of laminitis in horses; therefore, the early diagnosis of HGA is essential. In this study, we investigated changes in the plasma concentrations of lipopolysaccharide-binding protein (LBP) and serum amyloid A (SAA) as inflammatory markers in horses with laminitis. Sixteen healthy male Arabian horses that had cecal cannulation without visible laminitis or general symptoms were randomly divided into two groups. The horses were fed two different diets in a forage-to-concentrate ratio. Blood samples were collected on Days 1, 10, and 20. The primary objective of this study was to analyze plasma levels of LBP and SAA. Cecal specimens were obtained from each equine subject on three designated days: days 1, 10, and 20. The second objective was to assess the levels of pH and volatile fatty acids (VFA) in the samples. Throughout the study period, horses fed a high-concentrate diet exhibited a significantly elevated average lameness grade on days 10 and 20 compared to the initial stage (P < 0.001). On day 20, a significant increase in the concentration of SAA was observed in horses fed a high-concentrate diet, in contrast to the initial stage of the study. LBP levels in the plasma were significantly elevated on days 10 and 20 in horses fed a high-concentrate diet. Based on our findings, it is recommended that the evaluation of plasma LBP concentrations is more effective than SAA for the early identification of HGA in horses fed a high-grain diet.
This study was performed in the Geneva University Hospitals (HUG), a 2008-bed complex providing care for a population of ca. 500'000 inhabitants. All clinical samples sent for microbiological analysis within HUG are treated by the Bacteriology Laboratory of Geneva University Hospitals. An online database is kept up-to-date and includes all samples processed by the laboratory. The investigators performed a comprehensive analysis of all clinical samples included in this database over a 5-year period (2015-2020). This report focuses only on positive results for nontuberculous mycobacteria (NTM).The following items were recorded: age, gender, BMI whenever available, site of infection (when pulmonary: description of main radiological abnormalities), presence and type of immunosuppression, relevant pulmonary and non-pulmonary comorbidities, results of microscopy, and NTM species identified. The investigators also recorded whether the patient was treated for the identified NTM or not and if a susceptibility profile had been determined (this is not routinely performed and must be requested by the clinician).

The study protocol was approved by their local ethics committee
The invention relates to a medicine, in particular to a safflower tincture disinfectant and a brewing process thereof. The main components of the medicine are safflower, burred tuber, toad venom, camphor, borneol and ethanol. Adding Carthami flos, rhizoma Sparganii, Curcumae rhizoma, and Bufonis venenum into ethanol, cold soaking at room temperature, filtering, and adding Camphora and Borneolum Syntheticum into the filtrate to obtain reddish yellow transparent liquid. The medicine has the functions of eliminating dampness, killing parasite, dissipating heat, relieving pain, clearing away heat and toxic material, eliminating slough and promoting granulation. Has special effects on skin infection, carbuncle, sore and toxin, and traumatic injury. It also has obvious curative effect on arthralgia due to wind-cold-dampness, eczema and bed sore. Through clinical trials in a plurality of hospitals, the effective rate reaches 98 percent, and the cure rate reaches 94.5 percent. And has the advantages of low cost, simple and convenient use, no pain, no side effect and the like.
Non-active prewarming. Patients will be warmed using a surgical blanket during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
The present invention provides an athletic performance monitoring device having an accelerometer configured such that it can be worn by a user close to the center of gravity of the athlete; and a processing system including a global positioning system. The accelerometer is further configured such that it can wirelessly communicate acceleration data, relating to the acceleration of the user, to the processing system. In addition, the processing system is configured such that it can request acceleration data from the accelerometer only when some events depending on the output of the global positioning system and/or on a clock are occurring. It can also process the acceleration data it receives from the accelerometer to provide athletic performance information. There is further provided a corresponding method for providing athletic performance information. There is also provided an accelerometer for use in an athletic performance monitoring device.
The mechanisms involved in bilirubin neurotoxicity are still far from being fully elucidated. Several different events concur to damage mainly the neurons among which inflammation and alteration of the redox state play a major role. An imbalance of cellular calcium homeostasis has been recently described to be associated with toxic concentrations of bilirubin, and this disequilibrium may in turn elicit an inflammatory reaction. The different and age-dependent sensitivity to bilirubin damage must also be considered in describing the dramatic clinical picture of bilirubin-induced neurological damage (BIND) formerly known as kernicterus spectrum disorder (KSD). This review aims to critically address what is known and what is not in the molecular events of bilirubin neurotoxicity to provide hints for a better diagnosis and more successful treatments. Part of these concepts have been presented at the 38th Annual Audrey K. Brown Kernicterus Symposium of Pediatric American Society, Washington DC, May 1, 2023.
Each volunteer will receive a single dose of metformin on Day 1 followed by canagliflozin (JNJ-28431754) once daily on Days 4 to 7. On Day 8, volunteers will receive a single dose of canagliflozin in combination with a single dose of metformin.
Neuroinflammation plays a crucial role in the development of neurodegenerative protein misfolding disorders. This category of progressive diseases includes, but is not limited to, Alzheimer's disease, Parkinson's disease, and prion diseases. Shared pathogenesis involves the accumulation of misfolded proteins, chronic neuroinflammation, and synaptic dysfunction, ultimately leading to irreversible neuronal loss, measurable cognitive deficits, and death. Presently, there are few to no effective treatments to halt the advancement of neurodegenerative diseases. We hypothesized that directly targeting neuroinflammation by downregulating the transcription factor, NF-κB, and the inflammasome protein, NLRP3, would be neuroprotective. To achieve this, we used a cocktail of RNA targeting therapeutics (SB_NI_112) shown to be brain-penetrant, nontoxic, and effective inhibitors of both NF-κB and NLRP3. We utilized a mouse-adapted prion strain as a model for neurodegenerative diseases to assess the aggregation of misfolded proteins, glial inflammation, neuronal loss, cognitive deficits, and lifespan. Prion-diseased mice were treated either intraperitoneally or intranasally with SB_NI_112. Behavioral and cognitive deficits were significantly protected by this combination of NF-κB and NLRP3 downregulators. Treatment reduced glial inflammation, protected against neuronal loss, prevented spongiotic change, rescued cognitive deficits, and significantly lengthened the lifespan of prion-diseased mice. We have identified a nontoxic, systemic pharmacologic that downregulates NF-κB and NLRP3, prevents neuronal death, and slows the progression of neurodegenerative diseases. Though mouse models do not always predict human patient success and the study was limited due to sample size and number of dosing methods utilized, these findings serve as a proof of principle for continued translation of the therapeutic SB_NI_112 for prion disease and other neurodegenerative diseases. Based on the success in a murine prion model, we will continue testing SB_NI_112 in a variety of neurodegenerative disease models, including Alzheimer's disease and Parkinson's disease.
FIELD: organic chemistry. SUBSTANCE: invention relates to novel chemical compounds of aminomethane sulfonate class eliciting bactericidal activity, namely, to N-benzylideneamino-1-phenylmethane sulfonic acid diethylammonium salt of the formula (I)   and to method of its synthesis. Method of synthesis involves reaction of hydrobenzamide with complex of diethylamine with sulfurous anhydride and isopropyl alcohol followed by water addition at 25 C in isopropyl alcohol medium. The claimed compound in concentration 25-30 mg/ml in solution shows the stable bactericidal effect in 30 min of contact. EFFECT: improved method of synthesis, valuable antibacterial properties. 3 cl, 1 tbl, 4 ex
After a stroke the temporal course of microglial/macrophage activation is biphasic. The initial phase promotes neuroinflammation, while the later phase aids neurovascular recovery. Therefore the dynamics of stroke-induced cerebral microglial/macrophage activation are of substantial interest. In one embodiment, the present invention is directed to the use of novel anti-Iba-1-targeted superparamagnetic FePt nanoparticles immunocelles in conjunction with magnetic resonance imaging (MRI) to measure the spatiotemporal course of the activation of microglia/macrophages in brain tissue at 7, 14, and 28 days post-stroke. Ischemic cerebral lesion areas are identified using T2-weighted MR images. After injection of FePt nanoparticles as immunocelles, quantitative contrast changes in T2*-weighted MR images showed that the nanoparticles were taken up solely in brain regions that coincided with areas of microglial/macrophage activation detected by post-mortem immunohistochemistry. There was observed good agreement between the locations of the Fe+-cells, as shown by Perl's staining for iron, and the Iba-V-microgiia/macrophages, The time course of nanoparticle uptake paralleled the changes of microglial/macrophage activation and phenotypes measured by immunohistochemistry over the four week period post-stroke. Maximum microglial/macrophage activation occurred seven days post-stroke for both measures, and the diminished activation found after two weeks continued to four weeks. The results evidence that nanoparticle-enhanced MRI constitute a novel approach for monitoring the dynamic development of neuroinflammation in living animals during the progression and treatment of stroke and n eurodegenerative diseases. The implications and methods for diagnosis and monitoring therapy of stroke and other disease states and conditions are presented.
Application of 5,000 pulses of rESWT by a pneumatic generator, at a frequency of 20Hz on the most painful spot of the knee with 0 mJ/mm2 energy. The applications will also be given once a week for three weeks.
Gemcitabine (1250 mg/m2) IV on D 1, 8. Cisplatin (75 mg/m2) IV on D1 every 3 weeks.
Participants will receive placebo matching to unesbulin tablets administered orally twice weekly in each 3-week treatment cycle in combination with dacarbazine 1000 mg/m\^2 IV once every 21 days. Treatment will continue for each participant until evidence of unacceptable toxicity, disease progression, or treatment discontinuation for another reason.
The invention provides a sodium dimereaptopropane sulfonate injection and a capsule and a preparation method thereof. The preparation of the sodium dimereaptopropane sulfonate injection is peformed under the condition that sterilization is conducted for 10-20 minutes at the temperature of 121 DEG C or under the aseptic condition. The sodium dimereaptopropane sulfonate capsule comprises 0.09-0.11g/grain of sodium dimereaptopropane sulfonate. The preparation method comprises the steps of (1) weighing sodium dimereaptopropane sulfonate and using a 100-mesh sieve to sieve the sodium dimereaptopropane sulfonate, (2) weighing an auxiliary material and using the 100-mesh sieve to sieve the auxiliary material, (3) mixing the sodium dimereaptopropane sulfonate and the auxiliary material and using the 100-mesh sieve to sieve a mixture, and (4) calculating packable grain weight and filling the mixture into the capsule. The sterility assurance level in the preparation process of the sodium dimereaptopropane sulfonate injection is ensured to meet provisions of letters No. 7 (2008) of the registration department of the state supervision and administration bureau of food and drug--on Notice of Issuance of Basic Technical Requirements for Chemical Medicine Injection and Multi-component Biochemical Injection, and new application of the sodium dimereaptopropane sulfonate injection for treating hepatolenticular degeneration is provided. By means of the sodium dimereaptopropane sulfonate capsule and the preparation method, the problem that heavy metal poisoning sufferers are not suitable for injection dosing or long-term injection dosing is solved.
PURPOSE: A composition for promoting differentiation of human mesenchymal stem cells into adipocytes is provided to enhance skin volume. CONSTITUTION: An external use skin composition for enhancing skin elasticity contains 0.0001-30 wt% of extract of Castaneae Semen, Selaginella tamariscina, Aloe vera L., Mentha arvensis var. piperascens Makinv., Pinellia ternata (Thunb.) Breit., Triticum aestivum L., Saururus chinensis Baill., Polygala tenuifolia Willd., or Gleditsia sinensis Lam. as an active ingredient. The composition promotes differentiation of mesenchymal stem cells into adipocytes. The mesenchymal stem cells are derived from human. A pharmaceutical composition for promoting differentiation of adipocytes contains the extract as an active ingredient.
The invention relates to certain specific binding partners, in particular ligands and fragments, variants, mutants or derivatives for a receptor on the surface of activated T-cells eg activated CD4+ T-cells. Exemplary ligands are based on a ligand designated ACT-4-L-h-1. Preferred fragments include extracellular domains of ligands. In addition the invention provides certain binding moieties with specificity for the above-mentioned specific binding partners. Suitable binding moieties include humanized and human antibodies to the ligand. The invention further provides nucleic acid segments which code for such a specific binding partner or biding moiety as well as expression vectors and cell lines which include these. The invention further provides pharmaceutical compositions containing the specific binding partners or the binding moieties together with methods of using the specific binding partners and binding moieties in the treatment of various diseases and conditions of the immune system. Also provided by the invention are methods of monitoring activated T-cells e.g. activated CD4+ T-cells using the specific binding partners or fragments thereof, together with kits for use in these methods.